Peter Arn Learned to Make Growth Wait

A stranger walked into a hotel meeting room, looked at an unfamiliar rehabilitation prototype and sat on the wrong end. For Peter Arn and the early ROMTech team, this small piece of confusion was a gift. They had recruited people through Craigslist, offered each $25, put a chair beside the machine and resisted the urge to explain. Arn answered questions with another question: what do you think you should do with it?

The answer, expressed in body language, was that the object had failed to introduce itself. A patient tried to recline against the tapered rear as if it were the front. The team eventually placed the tablet at the front of the machine. It would display instructions and data, but it would also perform the humbler task of announcing where the front was.

There are cleaner founder stories. They begin with revelation, proceed through tasteful sketches and end with a product obediently matching its creator's vision. Arn's story is made of corrections. An adviser sketched an early concept on airplane napkins. Engineers built a heavy box with pedals. Employees applauded when the first crude version sent feedback to a tablet. Then actual users arrived and showed everyone what the object still could not explain.

Arn did not arrive in medical technology by the ceremonial route. His public career begins in mortgage lending around the turn of the century. He went on to build Calvin Capital Corporation, co-found Hoffman Financial Group and GoChuckGo, join the founding team at LIFERA, and work in marketing and acquisitions. By 2014, his work at ROM Technologies centered on global sales and investor relations. In August 2018, he became chief executive and chairman.

The industries changed. The recurring work did not. A young company needs someone to make an uncertain future sound coherent without pretending it is certain. That means hiring, selling, raising money and turning a crowded room of opinions into a sequence of decisions. ROMTech's short official biography puts product development, hiring and fundraising in Arn's remit from the beginning.

The mortgage years are easy to dismiss as prehistory. They also trained the muscles that later mattered. Lending requires an appetite for numbers, a sensitivity to risk and the ability to guide a hesitant person through a complicated decision. Investor relations adds a second audience: people willing to fund the future, provided someone can make the route legible. Medical technology raised the stakes and multiplied the constituencies, but it did not abolish the need for a patient explanation.

Arn's route also kept him close to the commercial side of invention. Engineers can make a device function. Clinicians can say whether its use makes sense. A field organization has to deliver it, a support team has to answer when it behaves strangely, and a finance operation has to make the entire arrangement survivable. The chief executive sits at the intersection, where every elegant departmental answer becomes someone else's inconvenient question.

One early colleague, Kelsey Szukhent, remembered an unexpected call from Arn. Ten minutes later they were face to face on Zoom. He needed help finding an engineer and wanted to start immediately. She later described his enthusiasm as contagious. The anecdote is revealing because the charisma has a destination: find the person, make the connection, get the work moving.

By 2023, Arn had been credited with spearheading capital raises of more than $200 million without venture capital. He had also built what he called a thousand-physician collective advising the company on product development, market development and new opportunities. The number matters less as a trophy than as a description of method. In a consequential market, expertise is scattered. The operator's advantage lies in collecting it without allowing the collection to become noise.

Arn calls ROMTech's process a feedback refinement loop. The phrase is almost aggressively sensible: listen, test, measure, adjust, repeat. Yet loops are hard on vanity. Each pass creates another opportunity for a cherished assumption to be contradicted by someone who has no obligation to admire it.

The first difficult patient testing felt, in Arn's later telling, devastating. That word is more useful than the customary language of friction and iteration. It admits that evidence can bruise. The team returned to patients and physicians, reworked the system and continued. A product became more intuitive because the company allowed disappointment to enter the room before defensiveness could lock the door.

The feedback also had to survive translation. A physician's request is not automatically a product specification. A patient's hesitation is not automatically resistance. Each observation has to be sorted: is this a training problem, an interface problem, a delivery problem or a deeper flaw in the premise? A loop earns its name only when information makes the return journey. Someone must show the clinician what changed, show the field team what was learned and let the next patient test the new assumption.

This habit reached beyond the product. Arn originated an internal Indiana Jones Award for colleagues who showed fast thinking and creative problem solving. It was deliberately stranger than employee of the month. A young company needs a little folklore, and this one made a hero of the person who could escape a pickle. Culture statements are easily framed. A memorable trophy makes the desired behavior visible.

The test of a founder changes once people want the thing. Early on, the job is to make belief contagious. Later, it is to keep belief from outrunning delivery. ROMTech entered 2025 with more demand than it could immediately fulfill. The tempting response was obvious: book the revenue and solve the capacity problem at speed.

Arn chose to moderate expansion while the company strengthened its operational infrastructure and clinical oversight. Some revenue waited. Patient volume still reached a reported 57,000 for the year, up 34 percent, but the more interesting number is the unreported one: the business the company decided it was not yet ready to take.

“In this industry, growing faster than your ability to deliver isn't ambition. It's risk,” Arn said. It is a line that would be true in many businesses, though not always with the same consequences. A software glitch may annoy. A weak service surrounding prescribed equipment can break trust among patients, clinicians and payors at once.

That choice connects the hotel-room prototype to the national operation. In both cases, the useful move was to let reality interrupt the preferred story. First, the device was not as obvious as its designers believed. Later, the organization was not yet as scalable as demand suggested. One correction moved a screen. The other slowed a sales engine. Both required the same unfashionable skill: accepting the constraint before it sent a larger invoice.

It also marks the point where an entrepreneur becomes a steward. The sales-minded founder is trained to remove objections. The steward must occasionally preserve one. Can the team support this patient volume? Can clinical oversight remain consistent? Can a device delivered far from headquarters still produce the intended experience? Those questions do not oppose growth. They determine whether growth arrives as an asset or a debt disguised as success.

Arn's ambition now extends beyond one orthopedic device. ROMTech has described pilots in cardiology, oncology, metabolic care and post-acute recovery. The company also sees value in the density of its real-world rehabilitation data, with the possibility of more personalized protocols and predictive tools. Arn is named among the inventors on active ROM Technologies patents, including work involving remote examination through augmented reality.

The expansion thesis is straightforward: guided movement, remote monitoring and engagement may travel wherever recovery depends on work done at home. The operational warning travels with it. Each new diagnosis introduces a fresh set of clinicians, protocols, risks and service demands. A reusable platform is not permission to skip the listening.

Arn's career offers a practical idea to borrow. Build a route by which reality can reach the people making decisions. It may be a thousand-physician network, a dashboard, a field technician, a stranger in a hotel room or an employee holding a tongue-in-cheek trophy. The form matters less than the route staying open.

Technology companies enjoy verbs such as disrupt, transform and scale. Arn's more durable verbs are quieter: listen, validate, improve, wait. They lack cinematic sparkle. They also describe how an awkward box becomes a service, how a sales story becomes an operation, and how growth becomes something a company can carry without dropping.